Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Accounts Payables: 2019-2025

Historic Accounts Payables for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $18.7 million.

  • BridgeBio Pharma's Accounts Payables rose 39.95% to $18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 39.95%. This contributed to the annual value of $9.6 million for FY2024, which is 9.73% down from last year.
  • Per BridgeBio Pharma's latest filing, its Accounts Payables stood at $18.7 million for Q3 2025, which was down 28.44% from $26.1 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Accounts Payables high stood at $27.5 million for Q1 2025, and its period low was $3.9 million during Q2 2023.
  • For the 3-year period, BridgeBio Pharma's Accounts Payables averaged around $12.8 million, with its median value being $10.7 million (2023).
  • In the last 5 years, BridgeBio Pharma's Accounts Payables plummeted by 60.62% in 2022 and then spiked by 482.17% in 2025.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Accounts Payables stood at $11.9 million in 2021, then dropped by 2.74% to $11.6 million in 2022, then decreased by 7.81% to $10.7 million in 2023, then fell by 9.73% to $9.6 million in 2024, then skyrocketed by 39.95% to $18.7 million in 2025.
  • Its Accounts Payables stands at $18.7 million for Q3 2025, versus $26.1 million for Q2 2025 and $27.5 million for Q1 2025.